Showing results (131-140 of 151) with videos related to
Sort By:
Pageof 16
Journal of Diabetes Research|June 9, 2022
Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE TrialTamara K Young, Nigel D Toussaint, Gian Luca Di Tanna, et al.Diabetes, Obesity & Metabolism|May 10, 2023
The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trialsAmy Kang, Brendan Smyth, Brendon L Neuen, et al.BMJ Open Diabetes Research & Care|June 13, 2023
Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose loweringDavid M Charytan, Kenneth W Mahaffey, Meg J Jardine, et al.Clinical Journal of the American Society of Nephrology : CJASN|November 20, 2020
Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m<sup>2</sup>: Subgroup Analysis of the Randomized CREDENCE TrialGeorge Bakris, Megumi Oshima, Kenneth W Mahaffey, et al.Journal of the American Heart Association|August 5, 2022
Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE TrialJing-Wei Li, Clare Arnott, Hiddo J L Heerspink, et al.American Journal of Nephrology|December 19, 2017
The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline CharacteristicsMeg J Jardine, Kenneth W Mahaffey, Bruce Neal, et al.American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 8, 2023
Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical TrialTae Won Yi, Brendan Smyth, Gian Luca Di Tanna, et al.American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|February 25, 2018
Scope and Consistency of Outcomes Reported in Randomized Trials Conducted in Adults Receiving Hemodialysis: A Systematic ReviewBénédicte Sautenet, Allison Tong, Gabrielle Williams, et al.Diabetes & Metabolism|February 16, 2022
The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trialJinlan Liao, Amy Kang, Chao Xia, et al.Clinical Kidney Journal|July 12, 2021
Methods and rationale of the DISCOVER CKD global observational studyRoberto Pecoits-Filho, Glen James, Juan Jesus Carrero, et al.Pageof 16